Seagen jumps as combination therapy succeeds in bladder cancer trial

Seagen

22/09/2023 12:52

** Shares of drugmaker Seagen  SGEN.O  rise ~3.7% to $214.10
premarket
    ** SGEN and Astellas Pharma's  4503.T  Padcev in combination
with Merck's  MRK.N  Keytruda met main goals in a late-stage
confirmatory trial for a type of bladder cancer 
    ** Cos say that the trial met overall survival (OS) and
progression-free survival (PFS) measures, compared with
chemotherapy
    ** OS determines the duration of patient survival from the
time of treatment initiation, while PFS looks at the time from
treatment until the cancer disease begins to worsen - NIH
    ** The combination therapy had received accelerated approval
from the U.S. health regulator in April 2023
    ** Up to last close, shares up 60.6% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))